OTCPK:CZMW.Y

Stock Analysis Report

Executive Summary

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Carl Zeiss Meditec's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.9%

CZMW.Y

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

27.6%

CZMW.Y

9.5%

US Medical Equipment

1.1%

US Market

CZMW.Y outperformed the Medical Equipment industry which returned 9.9% over the past year.

CZMW.Y outperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

CZMW.YIndustryMarket
7 Day2.9%0.7%-0.2%
30 Day-1.7%0.1%2.5%
90 Day7.7%2.5%1.6%
1 Year28.2%27.6%10.4%9.5%3.4%1.1%
3 Year199.8%194.6%69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Carl Zeiss Meditec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Carl Zeiss Meditec undervalued based on future cash flows and its price relative to the stock market?

61.03x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Carl Zeiss Meditec's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Carl Zeiss Meditec's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Carl Zeiss Meditec is overvalued based on earnings compared to the US Medical Equipment industry average.

Carl Zeiss Meditec is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Carl Zeiss Meditec is poor value based on expected growth next year.


Price Based on Value of Assets

Carl Zeiss Meditec is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Carl Zeiss Meditec expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

12.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Carl Zeiss Meditec's revenue is expected to grow by 7.5% yearly, however this is not considered high growth (20% yearly).

Carl Zeiss Meditec's earnings are expected to grow by 12.4% yearly, however this is not considered high growth (20% yearly).

Carl Zeiss Meditec's revenue growth is expected to exceed the United States of America market average.

Carl Zeiss Meditec's earnings growth is positive but not above the United States of America market average.

Carl Zeiss Meditec's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Carl Zeiss Meditec is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Carl Zeiss Meditec performed over the past 5 years?

16.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Carl Zeiss Meditec's year on year earnings growth rate has been positive over the past 5 years.

Carl Zeiss Meditec's 1-year earnings growth exceeds its 5-year average (23.9% vs 16.5%)

Carl Zeiss Meditec's earnings growth has not exceeded the US Medical Equipment industry average in the past year (23.9% vs 28.2%).


Return on Equity

Carl Zeiss Meditec has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Carl Zeiss Meditec used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Carl Zeiss Meditec's use of capital has not improved over the past 3 years (Return on Capital Employed).


Next Steps

Financial Health

How is Carl Zeiss Meditec's financial position?


Financial Position Analysis

Carl Zeiss Meditec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Carl Zeiss Meditec's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Carl Zeiss Meditec has no debt.

Carl Zeiss Meditec has no debt compared to 5 years ago when it was 0.2%.

Carl Zeiss Meditec has no debt, it does not need to be covered by operating cash flow.

Carl Zeiss Meditec has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Carl Zeiss Meditec has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Carl Zeiss Meditec's current dividend yield, its reliability and sustainability?

0.77%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Carl Zeiss Meditec's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Carl Zeiss Meditec's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Carl Zeiss Meditec is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Carl Zeiss Meditec is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Carl Zeiss Meditec's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Carl Zeiss Meditec's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Carl Zeiss Meditec's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Ludwin Monz (56yo)

9.5yrs

Tenure

€1,841,700

Compensation

Dr. Ludwin Monz, Ph.D., M.B.A. has been the Chairman of Management Board at Carl Zeiss Meditec AG since October 8, 2007. Dr. Monz has been the Chief Executive Officer and President of Carl Zeiss Meditec AG ...


CEO Compensation Analysis

Ludwin's remuneration is lower than average for companies of similar size in United States of America.

Ludwin's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.9yrs

Average Tenure

56yo

Average Age

The tenure for the Carl Zeiss Meditec management team is about average.


Board Age and Tenure

7.9yrs

Average Tenure

55yo

Average Age

The tenure for the Carl Zeiss Meditec board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jim Mazzo (62yo)

    Global President of Ophthalmology

    • Tenure: 3.2yrs
  • Martin Wiechmann

    Head of the Planetarium Business Unit

    • Tenure: 0yrs
  • Justus Wehmer (54yo)

    CFO & Member of the Management Board

    • Tenure: 0.9yrs
  • Ludwin Monz (56yo)

    President

    • Tenure: 9.5yrs
    • Compensation: €1.84m
  • Steven Schallhorn

    Chief Medical Officer for Global Ophthalmic Devices

    • Tenure: 2.9yrs
  • Sebastian Frericks

    Director of Investor Relations

    • Tenure: 0yrs
  • Mike Wang

    Head of Marketing - Shanghai

    • Tenure: 0yrs
  • Jan de Cler

    Head of Surgical Ophthalmology & Member of Management Board

    • Tenure: 0.9yrs

Board Members

  • Michael Kaschke (62yo)

    Chairman of Supervisory Board

    • Tenure: 9.5yrs
    • Compensation: €60.00k
  • Markus Guthoff (55yo)

    Member of the Supervisory Board

    • Tenure: 14.9yrs
    • Compensation: €50.00k
  • Christian Müller (52yo)

    Supervisory Board Member

    • Tenure: 0.5yrs
    • Compensation: €1.17m
  • Cornelia Grandy

    Employee Representative Member of Supervisory Board

    • Tenure: 7.9yrs
    • Compensation: €30.00k
  • Jörg Heinrich (61yo)

    Employee Representative Member of Supervisory Board

    • Tenure: 7.9yrs
    • Compensation: €35.00k
  • Tania von der Goltz (51yo)

    Deputy Chairwoman of the Supervisory Board

    • Tenure: 1.4yrs
    • Compensation: €21.50k

Company Information

Carl Zeiss Meditec AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Carl Zeiss Meditec AG
  • Ticker: CZMW.Y
  • Exchange: OTCPK
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €9.347b
  • Listing Market Cap: €10.329b
  • Shares outstanding: 89.44m
  • Website: https://www.zeiss.com/meditec-ag

Number of Employees


Location

  • Carl Zeiss Meditec AG
  • Goschwitzer Strasse 51-52
  • Jena
  • 7745
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AFXDB (Deutsche Boerse AG)YesBearer SharesDEEURMar 2000
AFXXTRA (XETRA Trading Platform)YesBearer SharesDEEURMar 2000
0DHCLSE (London Stock Exchange)YesBearer SharesGBEURMar 2000
CZMW.FOTCPK (Pink Sheets LLC)YesBearer SharesUSUSDMar 2000
AFXDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURMar 2000
AFXSWX (SIX Swiss Exchange)YesBearer SharesCHCHFMar 2000
AFXWBAG (Wiener Boerse AG)YesBearer SharesATEURMar 2000
CZMW.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDOct 2007

Biography

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Mi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:37
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.